News | August 27, 2009

New Lung Cancer Staging System to Impact Treatment Decisions

August 27, 2009 - The just-released 7th edition of the TNM (tumor, node, metastases) staging system for lung cancer will profoundly impact treatment decisions and patients' eligibility for clinical trials.

One in six lung cancer patients will receive a different staging category based on the 7th edition of the TNM staging system, reported Dr. Peter Goldstraw, chair of the staging project of the International Association for the Study of Lung Cancer (IASLC), at the association's World Conference on Lung Cancer.

Highlights of the new staging system for non-small cell lung cancer (NSCLC) include the following:

- New subcategories of stage T1 (early-stage) disease are based on size: Tumors measuring 2 cm or smaller will now be classified as T1a, whereas tumors larger than 2 cm and up to 3 cm will be classified as T1b. T2 disease will also be subdivided into T2a (tumors larger than 3 cm and up to 5 cm) and T2b (tumors larger than 5 cm and up to 7 cm).

- A new category (T3) will be used to describe tumors larger than 7 cm.

- Patients previously considered T4 because of additional tumor nodules in the same lung as the primary tumor will now be classified as T3. If these patients are node negative, they will be considered to have stage IIB disease.

- Patients with additional tumor nodules in the bilateral lung (previously M1) will now receive a designation of T4, and they will be down-staged from stage IV to stage IIIA.

- The presence of malignant pleural effusions, long referred to by oncologists as "wet IIIBs" and treated as if the patient had disseminated disease, will now be officially staged that way, as stage IV disease.

- Specifically, pleural dissemination will no longer be classified T4, but will now fall into a new category (M1a), the same designation given when additional nodules are found in the contralateral lung.

- Distant metastases will be subclassified within M1 as M1b disease.

- Staging changes will include the reclassification of patients with T2b tumors (5-7 cm) who have node-negative disease to stage IIA.

- Patients with T3 tumors (larger than 7 cm) will be considered to have stage IIB disease if they are node negative, but stage IIIA if they have associated features of M1, listed above.

The "N" classification within TNM that describes the number of involved lymph nodes will remain unchanged in the 7th edition.

The revisions to the TNM system are based on multidisciplinary contributions from the world lung cancer community, drawing on data compiled from more than 100,000 lung cancer cases from 46 centers in 19 countries. The IASLC led the revision effort, but both the International Union Against Cancer (UICC) and the American Joint Committee on Cancer (AJCC) have accepted the recommendations.

For more information: www.iaslc.org

Related Content

Philips Azurion Lung Edition supports high precision diagnosis and minimally invasive therapy in one room
News | Lung Imaging | September 21, 2020
September 21, 2020 — Philips introduced...
Final rule includes mandatory participation for nearly 1,000 practices and does not allow sufficient time for transition

Getty Images

News | Radiation Oncology | September 21, 2020
September 21, 2020 — In response to the September 18 ...
According to a new report published by P&S Intelligence, the global radiotherapy market is expected to expand from $7.2M in 2019 to $17M by 2030.

Image courtesy of Accuray

Feature | Radiation Therapy | September 21, 2020 | By Melinda Taschetta-Millane
According to a...
Breast cancer patients whose disease has spread to their brains fare better if their metastases are picked up before they begin to cause symptoms, according to a study presented at the 12th European Breast Cancer Conference.

Getty Images

News | Breast Imaging | September 21, 2020
September 21, 2020 — Breast cancer patients whose disease has spread to their brains fare better if their metastases
Data from latest research presented at the ESMO Virtual Congress 2020 suggests COVID-19 pandemic halts cancer care and damages oncologists' wellbeing

Getty Images

News | Coronavirus (COVID-19) | September 17, 2020
September 17, 2020 — Delays and cancellation of cancer treatments and other safety measures undertaken to minimize th
Varian Drives Next Evolution of Proton Treatment Planning with Eclipse v16.1
News | Treatment Planning | September 15, 2020
September 15, 2020 — Varian announced it has received FDA 510(k) clearance for its Eclipse v16.1 treatment planning s
High-intensity focused ultrasound (HIFU), a technology used to treat localized prostate cancer, has shown adequate control of prostate cancer while avoiding major side effects of surgery or radiation therapy, according to a new study in The Journal of Urology, Official Journal of the American Urological Association

Getty Images

News | Prostate Cancer | September 08, 2020
September 8, 2020 — Approved by the US Food and Drug Administration (FDA) in 2015 for prostate tissue ablation, the h
the Contrast Media Injectors Market is estimated to be USD 1.3 billion in 2020 and  projected to reach $1.9B by 2025, at a CAGR of 7.4% between 2020 and 2025

Getty Images

News | Contrast Media Injectors | September 02, 2020
September 2, 2020 — According to the new market research report "...
Single-dose radiotherapy replaces need for extra hospital visits, with benefits for patient safety and well-being

Getty Images

News | Women's Health | August 20, 2020
August 20, 2020— For most women with early breast cancer